TBE 31
TBE 31 is an orally active Keap1/Nrf2 pathway activator and NQO1 inducer with a Dm value of 1.1 nM for NQO1. TBE 31 binds to cysteine residues of Keap1, inhibits ubiquitination and degradation of Nrf2, thereby activating the expression of ARE-dependent genes. TBE 31 induces cytoprotective enzymes including NQO1 and GST isoforms, promotes Nrf2 accumulation, and upregulates Nrf2-regulated genes related to antioxidation and lipid metabolism. TBE 31 inhibits pro-inflammatory responses, formation of AFB1-DNA adducts, endoplasmic reticulum stress, cell apoptosis (apoptosis), hepatic fibrosis, oxidative stress, and the expression of ChREBP. TBE 31 reduces the number of tumors in a mouse model of ultraviolet-induced skin carcinogenesis. TBE 31 enhances nerve growth factor-induced neurite outgrowth. TBE 31 attenuates LPS-induced serum TNF-α levels and immobility time in mice. TBE 31 can be used in research related to liver cancer, skin cancer, inflammation-related depression, and non-alcoholic steatohepatitis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 936475-62-6
- Formel: C21H18N2O2
- Molecular Weight:330.38
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle TNF Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
NQO1 |
TNF-α |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Macrophage | IC50 |
0.056 nM
Compound: (+/-)-31
|
Antiinflammatory activity in CD-1 mouse Macrophage assessed as inhibition of IFN-gamma induced NO production after 48 hrs by Griess reaction
Antiinflammatory activity in CD-1 mouse Macrophage assessed as inhibition of IFN-gamma induced NO production after 48 hrs by Griess reaction
|
[PMID: 21361338] |
| RAW | IC50 |
1 nM
Compound: 4
|
Inhibition of interferon gamma-stimulated NO production in RAW 264.7 cells after 24 hrs
Inhibition of interferon gamma-stimulated NO production in RAW 264.7 cells after 24 hrs
|
[PMID: 17367124] |
| RAW264.7 | IC50 |
1 nM
Compound: 1, TBE-31
|
Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 48 hrs by Griess assay
Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 48 hrs by Griess assay
|
[PMID: 25965897] |
In Vitro
TBE 31 (48 h) potently induces NQO1 in Hepa1c1c7 cells, with a Dm value of 1.1 nM[1].
TBE 31 (0.25-1 μM; 24 h) potently induces ARE-dependent gene expression in AREc32 cells in a concentration-dependent manner in vitro[1].
TBE 31 (0.001-0.1 μM; 24 h) potently induces NQO1 in a concentration-dependent manner in wild-type MEF cells, and this induction depends on the transcription factor Nrf2[1].
TBE-31 binds reversibly to the thiol group in reduced dithiothreitol and the cysteine sensor of recombinant Keap1[2].
TBE-31 (0.001-0.1 µM; 4 days) enhances nerve growth factor-induced axonal outgrowth in PC12 cells in a concentration-dependent manner in vitro, reaching approximately 300% of the control level at the dose of 0.1 µM after 4 days of incubation[3].
TBE-31 (0.1 µM) upregulates Nrf2 protein levels and enhances nerve growth factor-induced axonal outgrowth in PC12 cells via an Nrf2-dependent mechanism[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | AUC0-24 | T1/2 (Elimination) |
|---|---|---|---|---|
| Mice[2] | 10 nmol/Kg | p.o. | 0.1955 nM·h/mL | 10.2 h |
In Vivo
TBE-31 (administered orally at 0.1-0.3 μM per 3 g of feed, once daily for 11 days) dose-dependently increases the activity and protein levels of cytoprotective enzymes by up to 5.0-fold in the liver, skin and stomach (but not the cerebral cortex) of healthy SKH-1 hairless mice, with no observed toxicity[1].
A single oral administration of TBE-31 (10 μM/kg) increases NQO1 activity by 2.4-fold in the liver and 1.5-fold in the heart of female C57BL/6 mice[2].
TBE-31 (40 nM per animal; topical administration; twice weekly; for approximately 30 weeks) significantly reduces the tumor number and burden in a UV-induced skin carcinogenesis mouse model with concurrent immunosuppression by Azathioprine (HY-B0256)[2].
TBE-31 (1-10 mg/kg; p.o.; single administration) exerts a dose-dependent anti-inflammatory effect on LPS (HY-D1056)-induced elevation of TNF-α, and significantly ameliorates LPS-induced depressive-like behaviors in mice at the dose of 10 mg/kg[3].
Treatment with TBE-31 (5 nM/g; p.o.; three times per week for 6 weeks) reverses diet-induced insulin resistance, alleviates hepatic steatosis, and improves non-alcoholic steatohepatitis (NASH) and liver fibrosis in diseased Nrf2+/+ mice; NAS is reduced by 40.8%, while glucose homeostasis, oxidative stress and inflammatory markers are all improved[4].
TBE-31 (5 nM/g; p.o.; three times per week; for 6 weeks) requires functional Nrf2 to improve insulin sensitivity, reduce hepatic steatosis, and alleviate non-alcoholic steatohepatitis (NASH) in mice with established diet-induced disease. These beneficial effects are completely abolished in Nrf2-/- mice, whereas the NAS is reduced by 52.9% in Nrf2+/+ mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SKH-1 hairless (female, 10-12 weeks old)[1]
-
Dosage:0.03 μM; 0.1 μM; 0.3 μM
-
Administration:topical; every 24 h; 3 doses
-
Result:Elevated NQO1 specific activity 3.5-fold (0.03 μmol dose), 4.2-fold (0.1 μM dose), and 4.9-fold (0.3 μM dose) compared to control.
Elevated GST specific activity 1.3-fold (0.03 μmol dose), 1.5-fold (0.1 μM dose), and 1.5-fold (0.3 μM dose) compared to control.
Induced statistically significant enzyme activity increases.
-
Animal Model:SKH-1 hairless (10-12 weeks old)[1]
-
Dosage:0.1 μM/3 g diet; 0.3 μM/3 g diet
-
Administration:oral; daily; 11 days
-
Result:Increased liver NQO1 activity 2.4-fold (0.1 μM dose) and 3.5-fold (0.3 μM dose); increased liver GST activity 2.4-fold (0.1 μM dose) and 3.7-fold (0.3 μM dose); increased liver GSTA1 protein levels 1.4-fold (0.1 μM dose) and 1.7-fold (0.3 μM dose); increased liver GSTM1 protein levels 1.6-fold (0.1 μM dose) and 1.9-fold (0.3 μM dose); increased liver GSTP1 protein levels 2.2-fold (0.1 μM dose) and 3.6-fold (0.3 μM dose).
Increased skin NQO1 activity 2.2-fold (0.1 μM dose) and 3.5-fold (0.3 μM dose); increased skin GST activity 1.3-fold (0.1 μM dose) and 2.0-fold (0.3 μM dose).
Increased stomach NQO1 activity 3.8-fold (0.1 μM dose) and 4.5-fold (0.3 μM dose); increased stomach GST activity 3.5-fold (0.1 μM dose) and 5.0-fold (0.3 μM dose); increased stomach GSTA1 protein levels 2.2-fold (0.1 μM dose) and 2.4-fold (0.3 μM dose); increased stomach GSTM1 protein levels 2.4-fold (0.1 μM dose) and 3.3-fold (0.3 μM dose); increased stomach GSTP1 protein levels 2.3-fold (0.1 μM dose) and 3.0-fold (0.3 μM dose).
Induced statistically significant enzyme activity and protein level increases.
Caused no observed toxicity.
Showed no changes in cerebral cortex cytoprotective enzyme activities or protein levels.
-
Animal Model:C57BL/6 (female, 6-12 weeks of age)[2]
-
Dosage:10 μM/kg
-
Administration:p.o.; single dose
-
Result:Increased hepatic NAD(P)H:quinone oxidoreductase 1 (NQO1) specific enzyme activity 2.4-fold compared to vehicle-treated controls.
Increased cardiac NQO1 specific enzyme activity 1.5-fold compared to vehicle-treated controls.
-
Animal Model:SKH-1 hairless[2]
-
Dosage:40 nM per animal
-
Administration:topical; twice weekly; ~30 weeks
-
Result:Dramatically reduced tumor multiplicity and burden compared to controls.
-
Animal Model:C57BL/6N (adult male, 20-26 g, LPS-induced inflammation-associated depression-like behavior)[3]
-
Dosage:1 mg/kg; 3 mg/kg; 10 mg/kg
-
Administration:p.o.; single dose
-
Result:Attenuated LPS-induced increases in serum TNF-α levels in a dose-dependent manner, with the 10 mg/kg dose reaching statistical significance.
Did not alter spontaneous locomotion in LPS-treated mice at 10 mg/kg.
Significantly reduced LPS-induced increases in immobility time in the TST and FST at 10 mg/kg compared to LPS-only treated mice.
Did not affect immobility time in control mice when administered alone.
-
Animal Model:C57BL/6 wild-type (Nrf2+/+) (male, 8-10 weeks of age, fed sequential high-fat plus 55% fructose (HF55Fr) diet for 15 weeks followed by high-fat plus 30% fructose (HF30Fr) diet for 9 weeks to induce NASH and insulin resistance)[4]
-
Dosage:5 nM/g body weight
-
Administration:p.o.; 3 times weekly; 6 weeks
-
Result:Enhanced glucose clearance during ITT and GTT, and reduced hepatic gluconeogenesis during PTT compared to vehicle controls.
Decreased post-intervention weight gain, fasted plasma insulin, plasma cholesterol, and plasma alanine aminotransferase activity relative to vehicle-treated HF-fed mice.
Decreased liver triglyceride and cholesterol levels, reduced mRNA expression of Adrp, increased hepatic mRNA for lipid catabolism genes (Acox2, Ces1g, Acot7, Ppara, Cpt1a, Scad), decreased expression of lipogenic transcription factors (Srebf1, Mlxipl, Lxra, Xbp1s) and their target lipid synthesis enzymes (Acaca, Acly, Fasn, Scd1, Dgat2, Lipin1, Mgpat), and increased mRNA for lipid export genes (Mttp, ApoB).
Reduced hepatic protein levels of Bip, phospho-Ire1α, Xbp1s, phospho-eIf2α, and Atf4, and decreased mRNA for Atf4 and Chop relative to vehicle controls.
Attenuated nuclear accumulation of NF-κB p65, p52, p50; increased IκBα protein; decreased phospho-IKKα/β and phospho-JNK; and reduced mRNA for proinflammatory genes (Cox2, Nos2, Il1β, Ifng, Tnfa, Mcp1, Elastase, Mpo) relative to vehicle controls.
Reduced cleavage of Parp, caspase-9, and caspase-3; increased Bcl-2 mRNA; and decreased mRNA for Tgfβ, Col1a1, and α-Sma relative to vehicle controls.
Decreased hepatic malondialdehyde and protein carbonyl levels, increased GSH/GSSG ratio, and induced mRNA for antioxidant Nrf2-target genes (Gclc, Gclm, Gpx2, Nqo1, Gstm1, Hmox1, Txn1, Txnrd1, Slc7a11, Cat, Prdx6) relative to vehicle controls.
Reduced NAFLD Activity Score (NAS) from 4.9 to 2.9, with significant decreases in hepatocyte ballooning and fibrosis relative to vehicle controls.
-
Animal Model:C57BL/6 wild-type (Nrf2+/+) and Nrf2-knockout (Nrf2-/-) (male, 8-10 weeks of age, fed high-fat plus 30% fructose (HF30Fr) diet for 10 weeks to induce NASH and insulin resistance)[4]
-
Dosage:5 nM/g body weight
-
Administration:p.o.; 3 times weekly; 6 weeks
-
Result:Enhanced insulin sensitivity during ITT and reduced hepatic gluconeogenesis during PTT compared to vehicle controls in Nrf2+/+ mice.
Reduced weight gain relative to vehicle-treated HF-fed mice in Nrf2+/+ mice.
Decreased liver triglyceride and cholesterol levels, reduced mRNA expression of Adrp, suppressed expression of lipogenic transcription factors (Srebf1, Lxra, Xbp1s) and their target lipid synthesis enzymes, and increased mRNA for lipid export genes (Mttp, ApoB) relative to vehicle controls in Nrf2+/+ mice.
Reduced hepatic protein levels of phospho-Ire1α, Xbp1s, p58IPK, phospho-eIf2α, and Atf4 relative to vehicle controls in Nrf2+/+ mice.
Attenuated nuclear accumulation of NF-κB p65 and p50, and reduced mRNA for Cox2 and Nos2 relative to vehicle controls in Nrf2+/+ mice.
Decreased hepatic malondialdehyde and protein carbonyl levels, and increased GSH/GSSG ratio relative to vehicle controls in Nrf2+/+ mice.
Reduced NAFLD Activity Score (NAS) from 2.125 to 1.0, with decreased steatosis and fibrosis relative to vehicle controls in Nrf2+/+ mice.
Showed no improvement in glucose homeostasis, weight gain, liver steatosis, ER stress, inflammation, oxidative stress, or liver histology relative to vehicle controls in Nrf2-/- mice; did not reduce liver triglyceride/cholesterol levels, suppress lipogenic gene expression, or mitigate NAS in Nrf2-/- mice.
Chemical Information
-
CAS. Nr. 936475-62-6
-
Molecular Weight 330.38
-
Formel C21H18N2O2
-
SMILES
C#C[C@]12C([C@@]3([C@@](C(C)(C(C(C#N)=C3)=O)C)([H])CC1)C)=CC(C(C#N)=C2)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
Cell differentiation
Cell differentiation refers to the process in which cells of the same origin gradually produce cell groups with different morphological structure and functional characteristics.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
PC12 NGF-induced neuronal-like differentiation
PC12 cells are a rat adrenal pheochromocytoma-derived clonal cell line that responds to nerve growth factor by stopping proliferation and extending neurites, producing a sympathetic neuron-like phenotype used to study neuronal differentiation and neurite outgrowth. NGF acts through TrkA-dependent signaling, and neurite outgrowth is associated with ERK/Akt signaling, microtubule organization, neuronal-marker expression, and increased electrophysiological neuronal features such as sodium-channel density. The main assay readout is morphological differentiation, usually measured as the percentage of neurite-bearing cells, neurite length, neurite number, or total neurite length per cell. Additional readouts include GAP-43, tyrosine hydroxylase, βIII-tubulin, neurofilament, synapsin I, synaptophysin, ERK phosphorylation, Akt phosphorylation, and sodium-channel current density.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
PC12 NGF-Induced Neuronal Differentiation Culture
PC12 cells are a rat adrenal pheochromocytoma clonal line that responds to NGF by stopping proliferation and extending branching neurite-like processes; after longer NGF exposure, cells develop long processes and neuronal-like ultrastructural and functional features. NGF-induced differentiation is read out mainly by neurite outgrowth, reduced proliferation, microtubule assembly, and neuronal differentiation-associated proteins such as MAPs, tau, GAP-43, and synapsin-1.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
SH-SY5Y Neuronal Differentiation Culture
SH-SY5Y neuronal differentiation culture uses sequential exposure to retinoic acid and neurotrophic factors to reduce proliferative neuroblastoma-like behavior and induce neuron-like morphology, including neurite extension, neuronal marker expression, and, in RA/BDNF protocols, greater synaptic-marker expression than undifferentiated culture. Retinoic acid is commonly used as the initiating differentiation cue, while BDNF in serum-reduced or serum-free medium supports later maturation and neurotrophic-factor-dependent neuron-like survival.
-
SH-SY5Y neuronal-like differentiation
SH-SY5Y neuronal-like differentiation uses defined culture conditions to shift proliferative human neuroblastoma cells toward a neuron-like state, mainly assessed by reduced proliferation, neurite extension, neuronal-marker expression, and, in some protocols, increased dependence on neurotrophic support. Retinoic acid (RA) is commonly used for the first differentiation phase, and sequential RA followed by brain-derived neurotrophic factor (BDNF) in serum-free medium is a well-characterized approach for generating neuron-like SH-SY5Y cultures with extensive neurite outgrowth. The primary readouts are morphology-based neurite outgrowth and marker-based confirmation using proteins such as βIII-tubulin, MAP2, GAP43, synaptophysin, NeuN, NSE, TH, or related neuronal/synaptic markers, depending on the study endpoint.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Reinheit & Dokumentation
Verweise
[1]. Dinkova-Kostova AT, et al. An exceptionally potent inducer of cytoprotective enzymes: elucidation of the structural features that determine inducer potency and reactivity with Keap1. J Biol Chem. 2010;285(44):33747-33755. [Content Brief]
[2]. Kostov RV, et al. Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action. Biochem Biophys Res Commun. 2015;465(3):402-407. [Content Brief]
[3]. Yao W, et al. Antidepressant effects of TBE-31 and MCE-1, the novel Nrf2 activators, in an inflammation model of depression. Eur J Pharmacol. 2016;793:21-27. [Content Brief]
[4]. Sharma RS, et al. Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2). Cell Mol Gastroenterol Hepatol. 2017;5(3):367-398. Published 2017 Dec 13. [Content Brief]
[5]. Onyango EO, et al. Synthesis of a dicyano abietane, a key intermediate for the anti-inflammatory agent TBE-31. Org Lett. 2014;16(1):322-324. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)